Microbiome-directed therapy for malnutrition represents a groundbreaking approach to addressing childhood undernutrition by targeting the gut microbiome, a critical determinant of health and growth outcomes. Traditional treatments, such as ready-to-use supplementary food (RUSF), primarily focus on providing calories but fail to address microbiome deficits.
Microbiome-directed therapy for malnutrition represents a groundbreaking approach to addressing childhood undernutrition by targeting the gut microbiome, a critical determinant of health and growth outcomes. Traditional treatments, such as ready-to-use supplementary food (RUSF), primarily focus on providing calories but fail to address microbiome deficits. Research highlights that malnourished children often exhibit immature gut microbiota resembling those of much younger, healthy children, indicating delayed microbial maturation. This disrupted microbiome contributes to poor nutrient absorption, immunity issues, and long-term growth impairments.
To counter this, scientists developed microbiota-directed complementary food (MDCF-2) aimed at restoring microbial maturity. Clinical studies comparing MDCF-2 to RUSF demonstrated that MDCF-2 promotes faster and more consistent growth recovery, despite containing fewer calories. Shotgun metagenomic sequencing identified key beneficial bacterial species, including *Prevotella copri* and *Gemmiger formicilis*, which are linked to improved growth and enriched carbohydrate metabolism pathways. This suggests enhanced energy extraction and nutrient utilization as mechanisms for its effectiveness.
Additionally, plasma proteome analysis revealed improved nutrient metabolism and immune function in children on MDCF-2, emphasizing its holistic impact. This strategy offers promise for transforming malnutrition management globally, focusing on sustainable microbiome restoration rather than calorie-heavy interventions, particularly in resource-limited settings.
Introduction: Anal squamous cell carcinoma is an increasingly common but largely preventable cancer. Most cases arise from persistent high-risk human papillomavirus (HPV) infection, progressing through high-grade squamous intraepithelial lesions (HSIL). This comprehensive review summarizes the...
Introduction: Acute infectious gastroenteritis can trigger persistent gastrointestinal symptoms long after the infection has resolved, leading to post-infection disorders of gut-brain interaction (PI-DGBI). This global Rome Foundation study evaluated the prevalence, risk factors, and clinical...
Introduction: Gut microbiota alterations have been implicated in the pathogenesis of irritable bowel syndrome (IBS), making fecal microbiota transplantation (FMT) a promising therapeutic strategy. However, clinical trials have reported conflicting results. This updated meta-analysis evaluated...
Introduction: Laparoscopic adhesiolysis offers several short-term advantages over open surgery for adhesive small bowel obstruction (ASBO). However, its long-term impact on recurrence, quality of life, and incisional hernia remains uncertain. The LASSO trial provides the...
Introduction: Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for...
Introduction: Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal emergencies in neonates. Early identification of infants requiring surgical intervention is critical but remains challenging. This study compared bedside abdominal ultrasonography (US) with abdominal...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.